1. Home
  2. AKRO vs BBUC Comparison

AKRO vs BBUC Comparison

Compare AKRO & BBUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • BBUC
  • Stock Information
  • Founded
  • AKRO 2017
  • BBUC 2022
  • Country
  • AKRO United States
  • BBUC United States
  • Employees
  • AKRO N/A
  • BBUC N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • BBUC
  • Sector
  • AKRO Health Care
  • BBUC
  • Exchange
  • AKRO Nasdaq
  • BBUC Nasdaq
  • Market Cap
  • AKRO 2.1B
  • BBUC 1.9B
  • IPO Year
  • AKRO 2019
  • BBUC N/A
  • Fundamental
  • Price
  • AKRO $33.61
  • BBUC $26.86
  • Analyst Decision
  • AKRO Strong Buy
  • BBUC
  • Analyst Count
  • AKRO 7
  • BBUC 0
  • Target Price
  • AKRO $43.20
  • BBUC N/A
  • AVG Volume (30 Days)
  • AKRO 538.4K
  • BBUC 38.6K
  • Earning Date
  • AKRO 11-15-2024
  • BBUC 01-01-0001
  • Dividend Yield
  • AKRO N/A
  • BBUC 0.96%
  • EPS Growth
  • AKRO N/A
  • BBUC 106.69
  • EPS
  • AKRO N/A
  • BBUC 7.20
  • Revenue
  • AKRO N/A
  • BBUC $7,704,000,000.00
  • Revenue This Year
  • AKRO N/A
  • BBUC N/A
  • Revenue Next Year
  • AKRO N/A
  • BBUC N/A
  • P/E Ratio
  • AKRO N/A
  • BBUC $3.59
  • Revenue Growth
  • AKRO N/A
  • BBUC 28.25
  • 52 Week Low
  • AKRO $13.39
  • BBUC $15.23
  • 52 Week High
  • AKRO $37.00
  • BBUC $27.00
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 67.66
  • BBUC 66.25
  • Support Level
  • AKRO $31.12
  • BBUC $23.35
  • Resistance Level
  • AKRO $35.88
  • BBUC $27.00
  • Average True Range (ATR)
  • AKRO 1.55
  • BBUC 0.79
  • MACD
  • AKRO 0.40
  • BBUC 0.20
  • Stochastic Oscillator
  • AKRO 81.63
  • BBUC 85.60

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About BBUC Brookfield Business Corporation Exchangeable Subordinate Voting Shares

Brookfield Business Corp is a company established as a vehicle that owns and operates certain services and industrial operations on a global basis and an alternative vehicle for investors who prefer investing in its operations through a corporate structure. Its goal is to generate returns through long-term capital appreciation with a modest distribution yield.

Share on Social Networks: